

## Review Article

# Emerging Role of Ferroptosis in Acute Kidney Injury

Zhaoxin Hu,<sup>1</sup> Hao Zhang ,<sup>1</sup> Shi-kun Yang ,<sup>1</sup> Xueqin Wu ,<sup>1</sup> Dong He,<sup>2</sup> Ke Cao,<sup>3</sup> and Wei Zhang <sup>1</sup>

<sup>1</sup>Department of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China

<sup>2</sup>Department of Respiration, The Second People's Hospital of Hunan Province of Hunan University of Chinese Medicine, Changsha, Hunan, China

<sup>3</sup>Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China

Correspondence should be addressed to Hao Zhang; zhanghaoliaoqing@163.com and Wei Zhang; weizhangxy@126.com

Received 17 June 2019; Revised 22 August 2019; Accepted 9 September 2019; Published 31 October 2019

Academic Editor: Víctor M. Mendoza-Núñez

Copyright © 2019 Zhaoxin Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute kidney injury (AKI) is a heterogeneous group of critical disease conditions with high incidence and mortality. Vasoconstriction, oxidative stress, apoptosis, and inflammation are generally thought to be the main pathogenic mechanisms of AKI. Ferroptosis is a type of iron-dependent nonapoptotic cell death characterized by membrane lipid peroxide accumulation and polyunsaturated fatty acid consumption, and it plays essential roles in many diseases, including cancers and neurologic diseases. Recent studies have revealed an emerging role of ferroptosis in the pathophysiological processes of AKI. Here, in the present review, we summarized the most recent discoveries on the role of ferroptosis in the pathogenesis of AKI as well as its therapeutic potential in AKI.

## 1. Introduction

Acute kidney injury (AKI), formerly known as acute renal failure (ARF), is a common and critical illness caused by multiple causes, including ischemia, nephrotoxic drugs, and urinary tract obstruction [1]. AKI occurs in approximately 5% of hospitalized patients and 30% of critically ill patients and has high morbidity and mortality [2]. Moreover, studies have shown that AKI increases the potential risk of chronic kidney disease and end-stage renal disease in patients [3–5]. In addition to blood purification, few therapeutics have made significant progress in the prevention of AKI. Thus, new targets or better regimens are still urgently needed to prevent AKI as well as to facilitate adaptive repair after the occurrence of AKI. The pathogenesis of AKI was previously believed to involve vasoconstriction, oxidative stress, apoptosis, inflammation, and hypoxia [6]. In 2012, Dixon et al. proposed a new concept of cell death, namely, ferroptosis [7], which was subsequently demonstrated to be involved in diseases such as cancers and in neurological disorders including Huntington disease and periventricular leukomalacia [8, 9]. A quite recent study shows that Hecpudin, a major regulator

of iron homeostasis, plays a protective role in AKI. This also provided a new evidence of the role of iron homeostasis in the pathogenesis of AKI and the therapeutic potential for AKI [10]. This review summarizes the current research progress on ferroptosis, its regulatory mechanisms, and its therapeutic potential in AKI (see graphic summary in Figure 1).

## 2. Definition, Process, and Measurement of Ferroptosis

Ferroptosis is iron-dependent nonapoptotic cell death and is characterized by the accumulation of membrane lipid peroxidation products and the consumption of plasma membrane polyunsaturated fatty acids. This kind of cell death can be induced by specific small molecules such as erastin and RAS-selective lethal 3 (RSL3) [11]. Ferroptosis has been reported to participate in various pathological processes of the brain, kidney, liver, and heart diseases [12]. In many cells, the import of cystine (Cys2) through system xc- is required for glutathione (g $\gamma$ -L-glutamyl-L-cysteinylglycine [GSH]) synthesis and maintains the function of glutathione peroxidase 4 (GPX4) [13]. Erastin (a ferroptosis inducer) can inhibit the




FIGURE 1: In renal tubular cells, abnormal increases in  $\text{Fe}^{2+}$  or  $\text{H}_2\text{O}_2$  caused by various pathogenic factors trigger the Fenton-like chemistry, which oxidizes membrane lipids to lipid peroxides, and mediate ferroptosis thus leading to AKI. RM initiates ferroptosis by raising the level of  $\text{Fe}^{2+}$ , while IRI induces ferroptosis by inhibiting the conversion of  $\text{Fe}^{2+}$  to  $\text{Fe}^{3+}$ . Other pathogenic factors such as FA, oxalate, cisplatin, and gentamicin can also promote the occurrence of Fenton-like chemistry, induce ferroptosis, and lead to AKI. The Fenton-like chemistry can be inhibited by intracellular GPX4, a key enzyme that maintains tissue homeostasis. Ferrostatin-1, liproxstatin, and DFO alleviate or delay the development of AKI by inhibiting the Fenton-like chemistry in a protective role in ferroptosis induced by various pathogenic factors. Note: AKI: acute kidney injury; RM: rhabdomyolysis; IRI: ischemia reperfusion injury; FA: folic acid; GPX4: glutathione peroxidase 4; DFO: deferoxamine.

import of Cys2, leading to GSH depletion and inactivation of phospholipid peroxidase and GPX4 [14, 15]. GSH depletion can lead to iron-dependent accumulation of reactive oxygen species (ROS), especially lipid ROS, which are themselves sufficient to kill cells [7].

Iron metabolism and lipid peroxidation signaling are thought to be central mediators of ferroptosis [16]. Circulating iron exists in the form of ferric iron ( $\text{Fe}^{3+}$ ) bound to transferrin.  $\text{Fe}^{3+}$  is introduced into the cell via the membrane protein transferrin receptor 1 (TFR1) and then localized to the endosome. In the endosomes, iron reductase reduces  $\text{Fe}^{3+}$  to ferrous iron ( $\text{Fe}^{2+}$ ). Finally, divalent metal transporter 1 (DMT1) mediates the release of  $\text{Fe}^{2+}$  from the endosomes into unstable iron pools in the cytoplasm. Excessive iron is stored in ferritin, an iron storage protein complex that includes ferritin light chain (FTL) and ferritin heavy chain 1 (FTH1) [17]. FTH has iron oxidase activity, which catalyzes the conversion of the ferrous form ( $\text{Fe}^{2+}$ ) to the ferric form ( $\text{Fe}^{3+}$ ), allowing iron to be safely incorporated into the ferritin shell, thereby reducing free iron levels [18]. Hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) can react with ferrous ions and produce hydroxyl radicals with strong oxidizing properties, this reaction is called Fenton reaction [19]. Excessive iron can lead to the production of ROS that mediate ferroptosis through Fenton-like chemistry [20].

Compared with other forms of regulatory cell deaths, such as apoptosis and autophagy, ferroptosis has unique morphological characteristics and biological manifestations. When ferroptosis occurs, the cell membrane ruptures and get blistered, the cell nucleus become lacking of chromatin condensation, the mitochondria decreases, mitochondria size decreases, the density of the bilayer membrane increases, the mitochondrial cristae decrease or disappear, and the mitochondrial outer membrane ruptures as observed under electron microscopy [17, 21]. However, whether mitochondrial damage plays a role in ferroptosis or just represents its irreversible result remains controversial [22]. The biological properties of ferroptosis are characterized by iron and ROS aggregation, which inhibit the activities of system xc- and GPX4 by reducing cystine uptake, depleting GSH, and releasing arachidonic acid and other molecules [13]. This process is different from neither apoptosis nor autophagy (see brief comparison in Table 1).

Along with the characteristics of ferroptosis described above, we usually assess ferroptotic cell death by cell death staining like TUNEL assay [17]. At the same time, we can measure the levels of  $\text{Fe}^{2+}$ , 4-hydroxynonenal (4HNE), and malondialdehyde (MDA) in tissues or cell lysate to assess iron-related lipid peroxidation [23, 24]. In addition, GPX4

TABLE 1: The differences between ferroptosis and other forms of cell death.

Cell death type	Ferroptosis	Apoptosis	Autophagy
Cell membrane	Rupture	Complete	Complete
Characteristic	Pathological cell death	Self-killing	Self-eating
Typical change	Iron-dependent lipid peroxidation	Caspase-dependent chromatin condensation	Autophagosome formation

and GSH levels should be tested to assess the inhibition of antioxidants during ferroptosis [24, 25]. We can further support ferroptosis by observing mitochondrial atrophy and rupture of the adventitia under transmission electron microscopy [26]. In another way, the application of ferroptosis inhibitors like ferrostatin-1 and liproxstatin-1 was also a necessary method to observe and demonstrate the occurrence of ferroptosis.

### 3. Key Regulators of Ferroptosis

**3.1. GPX4.** GPX4 was first isolated and purified from pig liver in 1982 by Ursini and colleagues, and its ability to inhibit iron-catalyzed lipid peroxidation in microsomes has been proven [15, 27]. GPX4 is one of the eight well-known GSH peroxidases in mammals. It is the only enzyme capable of reducing esterified oxidized fatty acids and cholesterol hydroperoxides [28], reducing lipid hydroperoxide (L-OOH) to a nontoxic lipid hydroxy derivative (L-OH). GSH is an essential intracellular antioxidant synthesized by glutamic acid (Glu), cysteine (Cys), and glycine (Gly) [29]. It can be used for enzymatic and nonenzymatic antioxidant reactions in cells and can maintain hydrogen peroxide levels within the physiological range. Cellular GSH levels are not depleted under normal physiological conditions [30]. GPX4 is a central enzyme that utilizes GSH to counteract lipoxygenase (Alox) activity and phospholipid/cardiolipin oxidation events, thus reducing peroxides at the expense of GSH or other thiol-containing compounds [31]. GPX4 is essential for maintaining tissue homeostasis and prevents cell death and tissue damage in multiple organs, including the brain, skin, and endothelium [32]. RSL3 induces ferroptotic cell death by binding and inactivating GPX4 [14]. GPX4 knockout in tubular cells results in massive cell deaths associated with the pathological form of ferroptosis [33]. In addition, sensitivity profiling in 177 cancer cell lines revealed that diffuse large B cell lymphomas and renal cell carcinomas were particularly susceptible to GPX4-regulated ferroptosis [14]. All of the above observations confirmed a negative regulation of ferroptosis by GPX4.

**3.2. System xc-.** System xc- is thought to be another important regulator of ferroptosis. It is the cystine/glutamate reverse transporter and consists of two subunits, xCT and 4F2hc. System xc- is one of many amino acid transporters expressed on the plasma membrane of mammalian cells, and it exchanges intracellular glutamate with extracellular cystine at a molar ratio of 1 : 1 [34]. Cystine is rapidly reduced to cysteine by systemic xc- uptake, which is used to synthesize proteins and GSH—the main endogenous antioxidant in mammalian cells [35]. Dietary cystine uptake and reab-

sorption in the kidney are important to maintain the required amino acid levels in the body. Early studies on monkeys have confirmed that xCT are mostly located at the brush border membrane of renal tubules, which is the anatomical location of amino acid transport in the kidney. It is important to emphasize that specific in-house developed antibodies were used to detect xCT expression in the kidney in this study [30]. Inhibition of system xc- can lead to a rapid decline in GSH levels and a rapid death of a variety of cell types *in vitro* [36]. Studies have found that ferroptosis induced by erastin was similar in many aspects to sulfasalazine- (SAS-) induced cell death, and SAS is a well-known system xc- inhibitor [7, 37]. Erastin, SAS, and sorafenib can block the uptake of radiolabeled cystine in cancer cells in culture [38]. Therefore, erastin appears to act as a direct inhibitor of system xc- function, suggesting that erastin induces ferroptosis through inhibiting system xc-. In addition, Beclin1 (BECN1), which is a key regulator of macroautophagy/autophagy and is involved in the production of the phosphatidylinositol 3-kinase (PtdIns3K) complex, was recently found to be a new driver of ferroptosis in a study showing that BECN1 may promote ferroptosis by regulating the activity of system xc- in cancer cells [39].

### 4. Ferroptosis and AKI

In geriatric and degenerative diseases, iron levels in the brain are inevitably elevated. The oxidative stress of excess iron is related to carcinogenesis [40–42], highlighting the involvement of ferroptosis. Recent findings have also revealed a link between ferroptosis and human diseases. The pathogenesis of AKI is very complicated, and the proximal tubule segment of the nephron is most susceptible to various forms of injury due to its anatomical features and complex functions [43]. A variety of molecular mechanisms have been proposed to induce or aggravate AKI, but ROS-induced renal damage is considered to be one of the key mediators [16, 44–46]. Multiple studies have suggested that ferroptosis is a promising therapeutic target, especially in diseases dominated by kidney tubular necrosis [47]. In a recent study using inducible GPX4-deficient mice, the mice died of massive renal tubular cell death and acute renal failure within 2 weeks after GPX4 deletion. The survival of the GPX4-deficient mice could be extended by approximately 35% by the clearance of lipid peroxides *in vivo* [33], further indicating an essential role of ferroptosis in kidney injury. More recently, studies on rhabdomyolysis and ischemia/reperfusion-induced AKI or other AKI models have provided additional direct evidence supporting the involvement of ferroptosis in AKI (Figure 1).

**4.1. Ferroptosis and AKI Caused by Rhabdomyolysis.** Rhabdomyolysis (RM) can be caused by strenuous exercise; direct trauma; and metabolic changes in the muscles; toxic effects of chemical, physical, or biological agents; and genetic factors [48–50]. Renal failure caused by RM accounts for 15% of all cases of acute renal failure [51]. Previous studies have suggested that the accumulation of myoglobin (Mb) in the kidney is the core mechanism leading to kidney damage. After lysis of myocytes, a large amount of salt, enzyme, and Mb are released in the circulation [52, 53], leading to circulating Mb deposition in the kidney which causes tubular obstruction and necrosis with strong renal vasoconstriction [54, 55]. Studies on RM-induced AKI indicate that  $\text{Fe}^{2+}$  produced by Mb metabolism directly induces lipid peroxidation in proximal tubular epithelial cells may be an important mechanism of RM-induced renal injury [56]. An animal model of myoglobinuria after intramuscular injection of glycerol is closely associated with human RM [57]. The free iron released by Mb degradation in the kidney participates in the production of oxidizing substances through the catalytic action of the Fenton reaction. Studies have shown that the use of the iron chelator deferoxamine can alleviate RM-induced renal injury in rats [58] and prevent direct exposure to Mb-induced cytotoxicity *in vitro* [59]. Guerrero-Hue et al. [60] demonstrated a key role for ferroptosis in RM-induced AKI and showed that ferroptosis-sensitive cell death can be inhibited by curcumin, a powerful antioxidant. Moreover, Zarjou et al. have reported that FTH knockout mice showed higher mortality and more severe kidney damage than the wild-type mice in RM-induced AKI model, indicating the protective effect of heavy chain ferritin against renal tubular injury and the role of iron ions in AKI [61]. Together, these studies have strongly suggested that ferroptosis plays an important role in RM-induced AKI.

**4.2. Ferroptosis and AKI Induced by Ischemia/Reperfusion.** Ischemia reperfusion injury (IRI) is characterized by a sudden pause in the blood supply to a particular organ and reoxygenation after restoration of blood flow. This process can exacerbate tissue damage by triggering an inflammatory cascade involving ROS, cytokines, chemokines, and leukocyte activation [62, 63]. In the kidney, IRI is one of the main causes of AKI. The pathophysiology of IRI in the kidney includes inflammation, oxidative stress and lipid peroxidation, mitochondrial dysfunction, renin-angiotensin system activation, and nitrite and nitric oxide accumulation [64]. In the past, apoptosis was considered the main regulated cell death in various models of ischemic injury. When necrotic apoptosis was found as a form of receptor interacting serine/threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like- (MLKL-) dependent regulatory necrosis, it was considered to be the leading cause of ischemic injury to the heart and kidney [65, 66]. However, later discovery suggested that ferroptosis might be a major driver of ischemic injury [67]. The application of ferrostatin in severe IRI models protected mice from functional acute renal failure and structural organ damage [68]; moreover, the RIPK1 inhibitor necrostatin-1 (Nec-1) did not protect the freshly isolated tubules from hypoxic injury. Clinically, renal

ischemia-reperfusion injury is the main cause of AKI in patients that have undergone cardiac surgery, and studies have shown that low levels of intraoperative iron-binding proteins may reflect an impaired ability to rapidly process catalytic iron released during extracorporeal circulation, leading to kidney damage [69], which highlights the importance of iron homeostasis in human ischemia-reperfusion injury and indicates that ferroptosis might be a potential therapeutic target in cardiac surgery-associated kidney injury or IRI-induced AKI.

**4.3. Ferroptosis in Folic Acid-Induced AKI.** Drugs and poisons are also common causes of AKI. Folic acid (FA) can cause AKI in rodents [70, 71], at a certain dose FA may form a crystal in the renal lumen [72] and at high doses FA is also directly toxic to tubular epithelium [73]. Lipid peroxidation in the kidney was found in animal models of FA-AKI, and mice pretreated with the ferrostatin-1 had improved renal function and reduced tissue damage [74]. However, this effect was not observed by inhibiting necrotic apoptosis or interfering with apoptosis at the pharmacological or genetic level. Therefore, ferroptosis is considered to be the main pathway for regulatory necrosis in FA-induced AKI.

**4.4. Ferroptosis and Other AKI Models.** Cisplatin is a widely used anti-tumor drug, and nephrotoxicity is its main side effect. Baliga et al. reported in 1998 that experiments with cisplatin-induced cytotoxicity models *in vitro* and cisplatin-induced acute renal failure *in vivo* demonstrated that exposure to cisplatin resulted in a significant increase in bleomycin-detectable iron [23]. The use of deferoxamine provided significant functional (measured by blood urea nitrogen and creatinine) and histological protection against cisplatin-induced acute renal failure. In the proximal tubule, FTH knockout mice [61] had more severe kidney damage after cisplatin administration than did the control mice. These studies have indirectly indicated a role for ferroptosis in cisplatin-induced kidney injury. However, further experimental validation using specific ferroptosis inhibitors and featuring more phenotypic observations of ferroptosis is needed in future studies on cisplatin-induced AKI.

In addition, reactive oxygen metabolites and scavengers of iron chelators also provide protection against oxalate crystals or gentamicin-induced nephrotoxicity [68, 75]. tert-Butyl hydroperoxide (tBHP) injured freshly isolated proximal tubules in an Fe-dependent fashion and that effect was ameliorated by a lipophilic antioxidant, diphenyl-p-phenylenediamine (DPPD). Protection against tBHP toxicity by deferoxamine and DPPD was accompanied by substantial suppression of thiobarbituric acid reactive substances (TBARS) accumulation [76]. These studies have directly or indirectly supported an essential role of ferroptosis in renal tubular injury.

## 5. Treatment of AKI by Targeting Ferroptosis

Ferrostatin-1 (Fer-1) acts by a redox reaction to prevent membrane lipid damage and thereby inhibit cell death [77]. It has been demonstrated to be able to reduce lipid peroxides

TABLE 2: Inducers and inhibitors of ferroptosis.

Ferroptosis inducer	Mechanism of action	Ferroptosis inhibitor	Mechanism of action
Erastin	Suppress system xc-	Ferrostatin-1	Reduce lipid peroxides
Sulfasalazine	Suppress system xc-	Liproxstatin	Reduce lipid peroxides
RSL3	Suppress GPX4	Deferoxamine	Reduce free iron
Sorafenib	Suppress system xc-	Vitamin E	Reduce free iron

to alcohols (R-OOH→R-OH) and/or to intercept and scavenge lipid groups by hydrogen atom transfer or direct reduction (R-O→R-OH) [78]. Ferrostatin is frequently reported to attenuate lipid peroxidation-mediated tissue damage in various diseases, including acute kidney disease. Liproxstatin, another featured inhibitor of ferroptosis, is a potent spiroquinoxalinamine derivative found by high-throughput screening that inhibits ferroptosis by lipid peroxide clearance *in vivo* [79]. Liproxstatin-1 was reported to suppress ferroptosis in human renal proximal tubule epithelial cells, in Gpx4<sup>-/-</sup> kidney, and in an IRI-induced tissue injury model [33]. In addition, lipid peroxidation inhibitors, such as lysyl oxidase (LOX) inhibitors, also inhibit ferroptosis [80]. Antioxidants and iron chelators (such as vitamin E and deferoxamine [DFO]) were also observed to inhibit ferroptosis by reducing iron availability [81] (commonly used inducers or inhibitors are summarized in Table 2). Most work on these ferroptosis inhibitors were performed in rodent AKI models or in *in vitro* experiments and lack clinical application potential. Future clinical work on AKI prevention or therapy targeting ferroptosis is needed.

## 6. Conclusion

Ferroptosis, which represents a unique form of regulated cell death, has been reported to be involved in the development of multiple cancers and neurologic diseases. An increasing number of studies have suggested a significant role of ferroptosis in acute kidney disease. In various AKI models, ferroptotic processes were observed and (or) inhibited by ferroptosis inhibitors, such as ferrostatin-1 and liproxstatin-1, to exert renal protection (Figure 1). The pathophysiologic processes of AKI are complicated by apoptosis, necrosis, and other forms of cell death. The extent to which ferroptosis is involved in AKI caused by different hazard factors remains largely unknown. In addition to the general controversial questions, such as the relationship between ferroptosis and iron, lipid peroxidation, oxidative stress injury, and mitochondrial autophagy also need to be further addressed in renal diseases. Ways in which we can benefit more from ferroptosis regulation to protect the kidneys from acute injury and even chronic impairment need to be considered. More comprehensive and in-depth research on ferroptosis in the field of renal diseases is needed to expand our knowledge and techniques against renal impairment to gain benefit in clinical outcomes in the future.

## Conflicts of Interest

The authors declare no conflict of interest, financial or otherwise.

## Authors' Contributions

Wei Zhang and Hao Zhang contribute equally to this work.

## Acknowledgments

The study was supported by grants from the National Natural Sciences Foundation of China (81470961 and 81870498).

## References

- [1] Y. Wang and Y. Tao, "Research progress on regulatory T cells in acute kidney injury," *Journal of Immunology Research*, vol. 2015, Article ID 174164, 9 pages, 2015.
- [2] R. Bellomo, J. A. Kellum, and C. Ronco, "Acute kidney injury," *The Lancet*, vol. 380, no. 9843, pp. 756–766, 2012.
- [3] S. G. Coca, S. Singanamala, and C. R. Parikh, "Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis," *Kidney International*, vol. 81, no. 5, pp. 442–448, 2012.
- [4] L. S. Chawla and P. L. Kimmel, "Acute kidney injury and chronic kidney disease: an integrated clinical syndrome," *Kidney International*, vol. 82, no. 5, pp. 516–524, 2012.
- [5] M. A. Venkatachalam, J. M. Weinberg, W. Kriz, and A. K. Bidani, "Failed tubule recovery, AKI-CKD transition, and kidney disease progression," *Journal of the American Society of Nephrology*, vol. 26, no. 8, pp. 1765–1776, 2015.
- [6] R. H. Thiele, J. M. Isbell, and M. H. Rosner, "AKI associated with cardiac surgery," *Clinical Journal of the American Society of Nephrology*, vol. 10, no. 3, pp. 500–514, 2015.
- [7] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., "Ferroptosis: an iron-dependent form of nonapoptotic cell death," *Cell*, vol. 149, no. 5, pp. 1060–1072, 2012.
- [8] S. W. Alvarez, V. O. Sviderskiy, E. M. Terzi et al., "NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis," *Nature*, vol. 551, no. 7682, pp. 639–643, 2017.
- [9] R. E. Speer, S. S. Karuppagounder, M. Basso et al., "Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke," *Free Radical Biology and Medicine*, vol. 62, pp. 26–36, 2013.
- [10] S. Swaminathan, "Iron homeostasis pathways as therapeutic targets in acute kidney injury," *Nephron*, vol. 140, no. 2, pp. 156–159, 2018.
- [11] H. Imai, M. Matsuoka, T. Kumagai, T. Sakamoto, and T. Koumura, "Lipid peroxidation-dependent cell death regulated by GPX4 and ferroptosis," in *Apoptotic and Non-apoptotic Cell Death*, S. Nagata and H. Nakano, Eds., vol. 403 of Current Topics in Microbiology and Immunology, pp. 143–170, Springer, Cham, 2017.
- [12] X. Sheng, C. Shan, J. Liu, J. Yang, B. Sun, and D. Chen, "Theoretical insights into the mechanism of ferroptosis suppression via inactivation of a lipid peroxide radical by liproxstatin-1," *Physical Chemistry Chemical Physics*, vol. 19, no. 20, pp. 13153–13159, 2017.

- [13] J. Y. Cao and S. J. Dixon, "Mechanisms of ferroptosis," *Cellular and Molecular Life Sciences*, vol. 73, no. 11-12, pp. 2195–2209, 2016.
- [14] W. S. Yang, R. SriRamaratnam, M. E. Welsch et al., "Regulation of ferroptotic cancer cell death by GPX4," *Cell*, vol. 156, no. 1-2, pp. 317–331, 2014.
- [15] F. Ursini, M. Maiorino, M. Valente, L. Ferri, and C. Gregolin, "Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides," *Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism*, vol. 710, no. 2, pp. 197–211, 1982.
- [16] S. J. Dixon and B. R. Stockwell, "The role of iron and reactive oxygen species in cell death," *Nature Chemical Biology*, vol. 10, no. 1, pp. 9–17, 2014.
- [17] Y. Xie, W. Hou, X. Song et al., "Ferroptosis: process and function," *Cell Death & Differentiation*, vol. 23, no. 3, pp. 369–379, 2016.
- [18] P. M. Harrison and P. Arosio, "The ferritins: molecular properties, iron storage function and cellular regulation," *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1275, no. 3, pp. 161–203, 1996.
- [19] M. Valko, H. Morris, and M. T. Cronin, "Metals, toxicity and oxidative stress," *Current Medicinal Chemistry*, vol. 12, no. 10, pp. 1161–1208, 2005.
- [20] S. Wang, J. Luo, Z. Zhang et al., "Iron and magnetic: new research direction of the ferroptosis-based cancer therapy," *American Journal of Cancer Research*, vol. 8, p. 1933, 2018.
- [21] S. Neitemeier, A. Jelinek, V. Laino et al., "BID links ferroptosis to mitochondrial cell death pathways," *Redox Biology*, vol. 12, pp. 558–570, 2017.
- [22] D. Wu and L. Chen, "Ferroptosis: a novel cell death form will be a promising therapy target for diseases," *Acta Biochimica et Biophysica Sinica*, vol. 47, no. 10, pp. 857–859, 2015.
- [23] R. Baliga, Z. Zhang, M. Baliga, N. Ueda, and S. V. Shah, "In vitro\_ and\_ in vivo\_ evidence suggesting a role for iron in cisplatin\_ induced nephrotoxicity," *Kidney International*, vol. 53, no. 2, pp. 394–401, 1998.
- [24] X. Y. Mao, H. H. Zhou, and W. L. Jin, "Ferroptosis induction in pentylenetetrazole kindling and pilocarpine-induced epileptic seizures in mice," *Frontiers in Neuroscience*, vol. 13, p. 721, 2019.
- [25] Y. Gong, N. Wang, N. Liu, and H. Dong, "Lipid peroxidation and GPX4 inhibition are common causes for myofibroblast differentiation and ferroptosis," *DNA and Cell Biology*, vol. 38, no. 7, pp. 725–733, 2019.
- [26] S. Doll and M. Conrad, "Iron and ferroptosis: A still ill-defined liaison," *IUBMB Life*, vol. 69, no. 6, pp. 423–434, 2017.
- [27] T. Hirschohorn and B. R. Stockwell, "The development of the concept of ferroptosis," *Free Radical Biology and Medicine*, vol. 133, pp. 130–143, 2019.
- [28] R. Brigelius-Flohe and M. Maiorino, "Glutathione peroxidases," *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1830, no. 5, pp. 3289–3303, 2013.
- [29] B. R. Stockwell, A. J. Friedmann, H. Bayir et al., "Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease," *Cell*, vol. 171, no. 2, article S0092867417131070X, pp. 273–285, 2017.
- [30] J. Burdo, R. Dargusch, and D. Schubert, "Distribution of the cystine/glutamate antiporter system xc<sup>-</sup> in the brain, kidney, and duodenum," *The Journal of Histochemistry and Cytochemistry*, vol. 54, no. 5, pp. 549–557, 2006.
- [31] M. Conrad and A. J. Friedmann, "Glutathione peroxidase 4 (Gpx4) and ferroptosis: what's so special about it?," *Molecular & Cellular Oncology*, vol. 2, no. 3, article e995047, 2015.
- [32] M. Wortmann, M. Schneider, J. Pircher et al., "Combined deficiency in glutathione peroxidase 4 and vitamin E causes multiorgan thrombus formation and early death in mice," *Circulation Research*, vol. 113, no. 4, pp. 408–417, 2013.
- [33] A. J. Friedmann, M. Schneider, B. Proneth et al., "Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice," *Nature Cell Biology*, vol. 16, no. 12, pp. 1180–1191, 2014.
- [34] S. Bannai, "Exchange of cystine and glutamate across plasma membrane of human fibroblasts," *Journal of Biological Chemistry*, vol. 261, p. 2256, 1986.
- [35] S. Bannai and N. Tateishi, "Role of membrane transport in metabolism and function of glutathione in mammals," *The Journal of Membrane Biology*, vol. 89, no. 1, pp. 1–8, 1986.
- [36] M. Conrad and H. Sato, "The oxidative stress-inducible cystine/glutamate antiporter, system xc<sup>-</sup>: cystine supplier and beyond," *Amino Acids*, vol. 42, no. 1, pp. 231–246, 2012.
- [37] P. W. Gout, A. R. Buckley, C. R. Simms, and N. Bruchovsky, "Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc<sup>-</sup> cystine transporter: a new action for an old drug," *Leukemia*, vol. 15, no. 10, pp. 1633–1640, 2001.
- [38] S. J. Dixon, D. N. Patel, M. Welsch et al., "Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis," *eLife*, vol. 3, article e2523, 2014.
- [39] R. Kang, S. Zhu, H. J. Zeh, D. J. Klionsky, and D. Tang, "BECN1 is a new driver of ferroptosis," *Autophagy*, vol. 14, no. 12, pp. 2173–2175, 2018.
- [40] M. Conrad, J. P. Angeli, P. Vandenabeele, and B. R. Stockwell, "Regulated necrosis: disease relevance and therapeutic opportunities," *Nature Reviews Drug Discovery*, vol. 15, no. 5, pp. 348–366, 2016.
- [41] S. Toyokuni, F. Ito, K. Yamashita, Y. Okazaki, and S. Akatsuka, "Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis," *Free Radical Biology and Medicine*, vol. 108, pp. 610–626, 2017.
- [42] S. L. Cramer, A. Saha, J. Liu et al., "Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth," *Nature Medicine*, vol. 23, no. 1, pp. 120–127, 2017.
- [43] S. M. Sancho-Martinez, J. M. Lopez-Novoa, and F. J. Lopez-Hernandez, "Pathophysiological role of different tubular epithelial cell death modes in acute kidney injury," *Clinical Kidney Journal*, vol. 8, no. 5, pp. 548–559, 2015.
- [44] A. Agarwal and H. S. Nick, "Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression," *Journal of the American Society of Nephrology*, vol. 11, pp. 965–973, 2000.
- [45] K. A. Nath, "Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues," *Kidney International*, vol. 70, no. 3, pp. 432–443, 2006.
- [46] D. Xu, M. Chen, X. Ren, X. Ren, and Y. Wu, "Leonurine ameliorates LPS-induced acute kidney injury via suppressing ROS-mediated NF- $\kappa$ B signaling pathway," *Fitoterapia*, vol. 97, pp. 148–155, 2014.

- [47] A. Linkermann, G. Chen, G. Dong, U. Kunzendorf, S. Krautwald, and Z. Dong, "Regulated cell death in AKI," *Journal of the American Society of Nephrology*, vol. 25, no. 12, pp. 2689–2701, 2014.
- [48] R. A. Brumback, D. L. Feeback, and R. W. Leech, "Rhabdomyolysis following electrical injury," *Seminars in Neurology*, vol. 15, no. 04, pp. 329–334, 1995.
- [49] D. R. Patel, R. Gyamfi, and A. Torres, "Exertional rhabdomyolysis and acute kidney injury," *The Physician and Sportsmedicine*, vol. 37, no. 1, pp. 71–79, 2009.
- [50] M. Gagliano, D. Corona, G. Giuffrida et al., "Low-intensity body building exercise induced rhabdomyolysis: a case report," *Cases Journal*, vol. 2, no. 1, p. 7, 2009.
- [51] O. Boutaud and L. N. Roberts, "Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure," *Free Radical Biology and Medicine*, vol. 51, no. 5, pp. 1062–1067, 2011.
- [52] A. L. Huerta-Alardin, J. Varon, and P. E. Marik, "Bench-to bedside review: Rhabdomyolysis – an overview for clinicians," *Critical Care*, vol. 9, article 158, 2005.
- [53] J. P. Knochel, "Mechanisms of rhabdomyolysis," *Current Opinion in Rheumatology*, vol. 5, no. 6, pp. 725–731, 1993.
- [54] R. Vanholder, M. S. Sever, E. Ereke, and N. Lameire, "Rhabdomyolysis," *Journal of the American Society of Nephrology*, vol. 11, no. 8, pp. 1553–1561, 2000.
- [55] G. Ayer, A. Grandchamp, T. Wyler, and B. Truniger, "Intrarenal hemodynamics in glycerol-induced myohemoglobinuric acute renal failure in the rat," *Circulation Research*, vol. 29, no. 2, pp. 128–135, 1971.
- [56] X. Bosch, E. Poch, and J. M. Grau, "Rhabdomyolysis and acute kidney injury," *The New England Journal of Medicine*, vol. 361, no. 1, pp. 62–72, 2009.
- [57] M. Fahling, S. Mathia, A. Paliege et al., "Tubular von Hippel-Lindau knockout protects against rhabdomyolysis-induced AKI," *Journal of the American Society of Nephrology*, vol. 24, no. 11, pp. 1806–1819, 2013.
- [58] M. S. Paller, "Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity," *The American Journal of Physiology*, vol. 255, no. 3, pp. F539–F544, 1988.
- [59] R. A. Zager and K. Burkhart, "Myoglobin toxicity in proximal human kidney cells: roles of Fe, Ca<sup>2+</sup>, H<sub>2</sub>O<sub>2</sub>, and terminal mitochondrial electron transport," *Kidney International*, vol. 51, no. 3, pp. 728–738, 1997.
- [60] M. Guerrero-Hue, C. Garcia-Caballero, A. Palomino-Antolin et al., "Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death," *The FASEB Journal*, vol. 33, no. 8, pp. 8961–8975, 2019.
- [61] A. Zarjou, S. Bolisetty, R. Joseph et al., "Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury," *The Journal of Clinical Investigation*, vol. 123, no. 10, pp. 4423–4434, 2013.
- [62] H. R. Jang and H. Rabb, "The innate immune response in ischemic acute kidney injury," *Clinical Immunology*, vol. 130, no. 1, pp. 41–50, 2009.
- [63] A. A. Sharfuddin and B. A. Molitoris, "Pathophysiology of ischemic acute kidney injury," *Nature Reviews Nephrology*, vol. 7, no. 4, pp. 189–200, 2011.
- [64] M. Malek and M. Nematbakhsh, "Renal ischemia/reperfusion injury; from pathophysiology to treatment," *Journal of Renal Injury Prevention*, vol. 4, pp. 20–27, 2015.
- [65] A. Linkermann, J. H. Brasen, M. Darding et al., "Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, pp. 12024–12029, 2013.
- [66] K. Newton, D. L. Dugger, A. Maltzman et al., "RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury," *Cell Death & Differentiation*, vol. 23, no. 9, pp. 1565–1576, 2016.
- [67] W. Tonnus and A. Linkermann, "The in vivo evidence for regulated necrosis," *Immunological Reviews*, vol. 277, no. 1, pp. 128–149, 2017.
- [68] A. Linkermann, R. Skouta, N. Himmerkus et al., "Synchronized renal tubular cell death involves ferroptosis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 47, pp. 16836–16841, 2014.
- [69] N. Choi, R. Whitlock, J. Klassen et al., "Early intraoperative iron-binding proteins are associated with acute kidney injury after cardiac surgery," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 157, no. 1, pp. 287–297.e2, 2018.
- [70] D. A. Long, K. L. Price, E. Ioffe et al., "Angiotensin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury," *Kidney International*, vol. 74, no. 3, pp. 300–309, 2008.
- [71] W. Brade, H. Herken, and H. J. Merker, "Regeneration of renal tubular cells after lesion by temporary ischaemia, folic acid, and 2,4,5-triamino 6-styrylpyrimidine," *Naunyn-Schmiedeberg's Archiv für Pharmakologie*, vol. 266, no. 1, pp. 95–100, 1970.
- [72] U. Schmidt, J. Torhorst, M. Huguenin, and U. C. Dubach, "Acute Renal Failure after Folate: NaKATPase in Isolated Rat Renal Tubule," *European Journal of Clinical Investigation*, vol. 3, no. 3, pp. 169–178, 1973.
- [73] M. Fink, M. Henry, and J. D. Tange, "Experimental folic acid nephropathy," *Pathology*, vol. 19, no. 2, pp. 143–149, 1987.
- [74] D. Martin-Sanchez, O. Ruiz-Andres, J. Poveda et al., "Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI," *Journal of the American Society of Nephrology*, vol. 28, no. 1, pp. 218–229, 2017.
- [75] R. Baliga, N. Ueda, P. D. Walker, and S. V. Shah, "Oxidant mechanisms in toxic acute renal failure," *American Journal of Kidney Diseases*, vol. 29, no. 3, pp. 465–477, 1997.
- [76] K. Sogabe, N. F. Roeser, M. A. Venkatachalam, and J. M. Weinberg, "Differential cytoprotection by glycine against oxidant damage to proximal tubule cells," *Kidney International*, vol. 50, no. 3, pp. 845–854, 1996.
- [77] P. Kabiraj, C. A. Valenzuela, J. E. Marin et al., "The neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells," *The Protein Journal*, vol. 34, no. 5, pp. 349–358, 2015.
- [78] R. Skouta, S. J. Dixon, J. Wang et al., "Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models," *Journal of the American Chemical Society*, vol. 136, no. 12, pp. 4551–4556, 2014.
- [79] O. Zilka, R. Shah, B. Li et al., "On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death," *ACS Central Science*, vol. 3, no. 3, pp. 232–243, 2017.

- [80] W. S. Yang, K. J. Kim, M. M. Gaschler, M. Patel, M. S. Shchepinov, and B. R. Stockwell, "Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 34, pp. E4966–E4975, 2016.
- [81] W. S. Yang and B. R. Stockwell, "Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells," *Chemistry & Biology*, vol. 15, no. 3, pp. 234–245, 2008.





Hindawi

Submit your manuscripts at [www.hindawi.com](http://www.hindawi.com)

